Response to Thoracic Radiotherapy in Patients with Small Cell Carcinoma of the Lung After Failure of Combination Chemotherapy

Radiology ◽  
1979 ◽  
Vol 132 (2) ◽  
pp. 443-446 ◽  
Author(s):  
Daniel C. Ihde ◽  
Frantisek S. Bilek ◽  
Martin H. Cohen ◽  
Paul A. Bunn ◽  
Joyce Eddy ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Combination Chemotherapy ◽  
Small Cell ◽  
Thoracic Radiotherapy

scholarly journals Small Cell Ovarian Cancer in Adolescents: Report of Two Cases and Review of the Literature

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
M. Rovithi ◽  
A. G. Pallis ◽  
A. Kalykaki ◽  
E. Lagoudaki ◽  
L. Giannikaki ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Combination Chemotherapy ◽  
Poor Prognosis ◽  
Relevant Literature ◽  
Malignant Neoplasm ◽  
Standard Of Care ◽  
Small Cell ◽  
Review Of The Literature

Ovarian small cell carcinoma is a rare and highly malignant neoplasm carrying a poor prognosis. Although combination chemotherapy remains the cornerstone of treatment due to the rarity of these tumors, no regimen can be recommended as standard of care although in the majority of cases platinum-based regimens are used. Herein, we report two cases of small cell carcinoma of the ovaries along with a review of the relevant literature.

Phase II trial of mitomycin-C in patients with small cell carcinoma of the lung after failure on combination chemotherapy

1984 ◽  
Vol 20 (12) ◽  
pp. 1477-1479 ◽  
Author(s):  
R.A Joss ◽  
J.P Obrecht ◽  
H.J Senn ◽  
P Alberto ◽  
C Sauter ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Mitomycin C ◽  
Small Cell Carcinoma ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Trial ◽  
Small Cell

Metastatic Small-Cell Carcinoma of Rectum Responding Dramatically to Combination Chemotherapy

1998 ◽  
Vol 21 (1) ◽  
pp. 75-76 ◽  
Author(s):  
Şuayib Yalçin ◽  
Yavuz Özşik ◽  
Gülten Tekuzman
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Combination Chemotherapy ◽  
Small Cell

Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung

2010 ◽  
Vol 96 (1) ◽  
pp. 78-83 ◽  
Author(s):  
Don Yee ◽  
John Hanson ◽  
Charles Butts ◽  
Anthony Reiman ◽  
Anil Joy ◽  
...  
Keyword(s):  
Phase I ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Dose Escalation ◽  
Small Cell ◽  
External Beam ◽  
Thoracic Radiotherapy ◽  
Limited Stage

Combination Chemotherapy and Radiotherapy for Small-Cell Carcinoma of the Esophagus: A Case Report of Long-Term Survival and Review of the Literature

1991 ◽  
Vol 16 (2) ◽  
pp. 97-98
Author(s):  
Atif M. Hussein ◽  
Lynn G. Feun ◽  
Kasi S. Sridhar ◽  
Pasquale Benedetto ◽  
Stuart Waldman ◽  
...  
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Combination Chemotherapy ◽  
Small Cell ◽  
Review Of The Literature ◽  
Term Survival ◽  
Carcinoma Of The Esophagus ◽  
Long Term Survival

Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.

1984 ◽  
Vol 2 (11) ◽  
pp. 1192-1199 ◽  
Author(s):  
J R Daniels ◽  
L Y Chak ◽  
B I Sikic ◽  
P Lockbaum ◽  
M Kohler ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Combination Chemotherapy ◽  
Initial Treatment ◽  
Disease Free Survival ◽  
Small Cell ◽  
Limited Disease ◽  
Whole Brain Radiation ◽  
Sequential Schedule ◽  
Field Radiation

One hundred forty-seven eligible patients with small-cell carcinoma of the lung (SCCL) have been randomized to receive alternating (A) or sequential (S) combination chemotherapy. Initial treatment was with three cycles of VAM (A) or two cycles of POCC (S). VAM consists of VP16-213 200 mg/m2 intravenously (IV) day 1, Adriamycin (Adria Laboratories, Columbus, Ohio) 50 mg/m2 IV day 1, and methotrexate 30 mg/m2 IV day 1 repeated at 21-day intervals. POCC consists of cyclophosphamide 600 mg/m2 IV days 1 and 8, vincristine 1.5 mg/m2 (maximum, 2 mg) IV days 1 and 8, CCNU 60 mg/m2 po day 1, and procarbazine 100 mg/m2 po days 2 through 15. After initial treatment, all patients received whole brain radiation therapy (3,000 rad/10 fractions/2 wk). Patients with limited disease in addition received irradiation encompassing the tumor, hilar, mediastinal, and supraclavicular regions (5,000 rad/25 fractions/5 wk). After radiation, patients on arm A received POCC alternating with VAM; patients on arm S received POCC until progression when they were to be treated with VAM. The alternating arm was superior with respect to rate of complete remission (CR), median disease-free survival (MDFS), and median survival (MS). The advantage of alternating therapy was not as clearly demonstrated in the limited disease groups when interposition of involved field radiation delayed the initiation of the alternating schedule. In limited disease alone, comparing arm A with arm S, no statistically significant differences were noted. The CR rate was 42% v 54%, MDFS was 14 v 10 months, and MS was 16 v 10 months. In extensive disease, the CR rate was 44% v 20% (P = .03), MDFS was 6 v 4 months (P = .003), and MS was 10 v 7 months (P = .001). Improved treatment outcome in SCCL is achieved when combination chemotherapy regimens of similar effectiveness are administered in an alternating rather than sequential schedule.

Sign in / Sign up

Export Citation Format

Share Document